B-Cell Leukemia Clinical Trials

6 recruitingLast updated: June 18, 2026

There are 6 actively recruiting b-cell leukemia clinical trials across 4 countries. Studies span Phase 1, Phase 2, Early Phase 1. Top locations include Bethesda, Maryland, United States, Calgary, Alberta, Canada, Guangzhou, Guangdong, China. Updated daily from ClinicalTrials.gov.


B-Cell Leukemia Trials at a Glance

6 actively recruiting trials for b-cell leukemia are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Bethesda, Calgary, and Guangzhou. Lead sponsors running b-cell leukemia studies include Arkansas Children's Hospital Research Institute, British Columbia Cancer Agency, and National Cancer Institute (NCI).

Browse b-cell leukemia trials by phase

Treatments under study

About B-Cell Leukemia Clinical Trials

Looking for clinical trials for B-Cell Leukemia? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new B-Cell Leukemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about B-Cell Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 1Phase 2

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Acute Lymphoblastic LeukemiaLymphoma, Non-HodgkinB-cell Lymphoma+8 more
National Cancer Institute (NCI)130 enrolled1 locationNCT05442515
Recruiting
Phase 1Phase 2

CAR-T Immunotherapy Targeting CD19- ALL

B-Cell Leukemia
Shenzhen Geno-Immune Medical Institute100 enrolled3 locationsNCT04016129
Recruiting
Phase 1

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaMantle Cell Lymphoma+5 more
British Columbia Cancer Agency24 enrolled7 locationsNCT06208735
Recruiting

A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

B-cell Acute Lymphoblastic LeukemiaB-Cell Lymphoblastic LeukemiaB-cell Acute Lymphoblastic Leukemia (B-ALL)+5 more
Arkansas Children's Hospital Research Institute300 enrolled2 locationsNCT07422337
Recruiting
Early Phase 1

Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

B-cell LymphomaB-cell MalignancyB-Cell Leukemia
Wondercel Biotech (ShenZhen)30 enrolled1 locationNCT06662227
Recruiting
Phase 1

Clinical Trial To Assess the Efficacy and Safety of PMCC-COE19 in Patients with CD19-Expressing B-Cell Malignancies

CD19 Positive Malignant B-cell LeukemiaCD19 Positive Malignant B-cell LymphomaCD19 expressing malignancies
Peter MacCallum Cancer Centre12 enrolled1 locationACTRN12625001195448